International Journal of Hematology

DOI: 10.1007/s12185-018-2443-1 Pages: 1-9

PAS positivity of erythroid precursor cells is associated with a poor prognosis in newly diagnosed myelodysplastic syndrome patients

1. Kyoto University Hospital, Department of Clinical Laboratory

2. Kanazawa Medical University, Department of Hematology and Immunology

3. Kyoto University, Department of Hematology and Oncology, Graduate School of Medicine

4. Kyoto University, Department of Clinical Laboratory Medicine, Graduate School of Medicine

5. Kyoto University, Human Health Science, Graduate School of Medicine

Correspondence to:
Yasuhiko Kamikubo
Tel: +81-75-751-3928
Email: kamikubo.yasuhiko.7u@kyoto-u.ac.jp

Close

Abstract

Myelodysplastic syndrome (MDS) is a group of clonal stem cell disorders characterized by hematopoietic insufficiency. The accurate risk stratification of patients with MDS is essential for selection of appropriate therapies. We herein conducted a retrospective cohort study to examine the prognostic value of periodic acid-Schiff (PAS) reaction-positive erythroblasts in MDS patients. We examined the PAS positivity of the bone marrow erythroblasts of 144 patients newly diagnosed with MDS; 26 (18.1%) of them had PAS-positive erythroblasts, whereas 118 (81.9%) did not. The PAS-positive group showed significantly poorer karyotypes as defined in the revised International Prognostic Scoring System (IPSS-R) and higher scores in age-adjusted IPSS-R (IPSS-RA) than the PAS-negative group. Overall survival (OS) and leukemia-free survival (LFS) were also significantly shorter in the PAS-positive group than in the PAS-negative group. Similar results were obtained when only high- and very high risk groups were analyzed using IPSS-RA. This retrospective study suggested that the PAS positivity of erythroblasts is an additional prognostic factor combined with other risk scores for OS and LFS in MDS, and our results may contribute to improved clinical decision-making and rapid risk stratification.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge